• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years

February 28, 2017 By Sarah Faulkner

Elixir MedicalElixir Medical's DeSyne stent tops Medtronic's Endeavor after 5 years‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial.

The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent.

The device emits a low dose of either novolimus or zotarolimus from a thin coating around the stent system. The thin polymer coating degrades over the course of 6 – 9 months, leaving behind a bare metal cobalt chromium stent.

Previous work has shown both noninferiority and superiority of the novolimus-eluting stent compared to the zotarlimus-eluting stent for in-stent lumen loss.

In the long-term, 5 year follow-up study, researchers observed that Elixir’s stent was associated with lower incidence of the patient-oriented composite endpoint, including death, myocardial infarction and revascularization. The data also showed that Elixir’s device was associated with a lower incidence of the device-oriented composite endpoint, including cardiac death and clinically indicated target lesion revascularization.

While there was no difference in cardiac death and definite stent thrombosis between the 2 groups, the researchers said that Elixir’s DeSyne stent was associated with a trend toward reduction in myocardial infarction and repeat revascularization.

Elixir won CE Mark approval for its DeSyne stent in 2012, based on results from the Excella BD study which compared the drug-eluting stent to Medtronic’s Endeavor system.

At 6 months, DeSyne proved superior to Endeavor for in-stent late lumen loss and binary restenosis, according to the company.

In May 2012, Elixir touted 1st-in-man clinical results for its DeSolve fully bioabsorbable drug-eluting scaffold system, which is also coated in novolimus. Unlike the company’s DeSyne stent, which degrades and leaves behind a bare metal implant, DeSolve is designed to be absorbed by the body in 1-2 years.

The DeSolve study observed 15 patients over 6 months, finding “excellent” late lumen loss, no re-blockage of the artery, no incidents of stent thrombosis and 1 major adverse cardiac event, according to a press release.

Filed Under: Clinical Trials, Featured, Vascular, Wall Street Beat Tagged With: Elixir Medical Corporation, Medtronic

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Reader Interactions

Comments

  1. riya sen says

    March 19, 2019 at 5:18 am

    Nice Article .Thanks For Sharing

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS